comparemela.com

Latest Breaking News On - Rigel pharmaceuticals inc - Page 7 : comparemela.com

Rigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Market

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL), Thursday announced that it has agreed to acquire the U.S. rights to Gavreto from Blueprint Medicin.

Rigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Market

Rigel Pharmaceuticals, Inc. (RIGL), Thursday announced that it has agreed to acquire the U.S. rights to Gavreto from Blueprint Medicines Corp. for an initial payment of $10 million, followed by an additional $5 million after one year of the closing date.

Rigel takes on US marketing of Blueprint s Gavreto

Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.